This Article Full Text Full Text (PDF) All Versions of this Article: 48/4/546    most recent 01.HYP.0000241985.54400.85v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Taddei, S. Articles by Ghiadoni, L. Search for Related Content PubMed PubMed Citation Articles by Taddei, S. Articles by Ghiadoni, L. Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure Related Collections Cardiovascular Pharmacology Peripheral vascular disease Clinical Studies Endothelium/vascular type/nitric oxide Other Vascular biology Related Article

(Hypertension. 2006;48:546.)
© 2006 American Heart Association, Inc.

Editorial Commentaries

Phosphodiesterase 5 Inhibition to Treat Essential Hypertension

Is This the Beginning of the Story?

Stefano Taddei; Lorenzo Ghiadoni

From the Department of Internal Medicine, University of Pisa, Italy.

Correspondence to Stefano Taddei, Department of Internal Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy. E-mail s.taddei@int.med.unipi.it

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Treatment of hypertension is a challenging task in cardiovascular medicine. The obviously simple concept that blood pressure (BP) must be "normalized" faces the intrinsic difficulty to decrease BP values, because the effectiveness of available drug classes in terms of BP reduction is in many cases not adequate to reach the therapeutic targets.¹ One possible means of overcoming this limitation is to combine drugs with different mechanisms of action to obtain a synergistic effect on BP reduction.¹ The more drug classes that are available, the more possibilities we have to obtain an effective BP control.

The article from Oliver et al² published in this issue of Hypertension represents the first study performed with an accurate experimental design and methodology demonstrating that inhibitors of isoform 5 of phosphodiesterase (PDE) might be potentially used as a new drug class for the treatment of essential hypertension. PDE is a family of isoenzymes with various tissue and cellular distribution and linkage to specific cGMP- and cAMP-dependent pathways³ (Figure). To date, 11 PDE isoforms have been identified, and their tissue distribution together with the availability of specific antagonists is the basis for a potential clinical use of PDE inhibitors.³ PDE 5, a cGMP-hydrolyzing isoform, is highly expressed in vascular smooth muscle cells of the corpora cavernosa, but it is also well represented in various other tissues, including peripheral, coronary, and pulmonary vessels. Sildenafil is a specific inhibitor of PDE 5 isoform and, therefore, increases intracellular cGMP concentration by inhibiting its breakdown with the consequence . . . [Full Text of this Article]

Related Article:

Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension

James J. Oliver, Vanessa P. Melville, and David J. Webb
Hypertension 2006 48: 622-627. [Abstract] [Full Text] [PDF]